Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease

详细信息    查看全文

• 作者：Yngvar Flø ; isand¹ ; ^yfl70@me.com ; Knut E.A. Lundin¹ ; ² ; ³ ; ⁴ ; Vladimir Lazarevic⁵ ; Jø ; rn Dehli Kristiansen¹ ; Liv T.N. Osnes⁶ ; Geir E. Tjø ; nnfjord¹ ; ³ ; Henrik Mikael Reims⁷ ; Tobias Gedde-Dahl¹
• 关键词：Graft-versus-host disease ; Stem cell transplant ; Vedolizumab ; Gut GVHD ; Integrin ; Steroid refractory
• 刊名：Biology of Blood and Marrow Transplantation
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：23
• 期：1
• 页码：172-175
• 全文大小：1357 K
• 卷排序：23

文摘

Integrin α4β7 is involved in T cell alloreactivity in acute graft-versus-host disease (GVHD) of the gut. Vedolizumab, a monoclonal antibody, targets the homing of T cells to the intestinal endothelium through inhibition of binding of integrin α4β7. Six patients were treated with vedolizumab for grade IV gut GVHD with clinical responses. The findings presented in this case series give hope for novel therapy of steroid-refractory intestinal GVHD.